Moderna表示Spikevax加强针可触发对Omicron的更高保护

2021-12-22 Allan MedSci原创

与加强前相比,额外注射100μg剂量水平的 Spikevax 可使抗体水平上升 83 倍。

本周一,Moderna 公布了实验室测试的早期数据,表明其 COVID-19 疫苗 Spikevax 的加强剂量似乎对 Omicron 变体具有保护作用,Moderna首席执行官 Stéphane Bancel 表示,初步调查结果“令人振奋”,但尚未经过同行评审。

Moderna 正在寻找不同的策略来解决新出现的关注变体 (VOC)--Omicron。除了测试其现有疫苗的加强针外,它还在开发多价候选疫苗,称为 mRNA-1273.211 和 mRNA-1273.213,它们结合了以前的 VOC。此外,该公司正在开发专门针对 Delta 和 Omicron 的加强针。

周一的调查结果包括来自 20 名加强针接受者的血清,每人接受50μg和100 μg剂量水平的Spikevax;50μg和100μg剂量水平的mRNA-1273.211;100μg剂量水平的mRNA-1273.213。Moderna称,Spikevax 的两剂疗程产生了针对 Omicron 的“低”中和抗体,但是当给予已经批准的 50μg 相同疫苗加强时,抗体增加了 37 倍。此外,与加强前相比,额外注射100μg剂量水平的 Spikevax 可使抗体水平上升 83 倍。

该公司表示,其多价候选药物在两种剂量下都将 Omicron 特异性中和抗体提高到“类似的高水平”。尽管如此,鉴于 Omicron 的快速传播,考虑到它产生的中和效价的强度以及部署新疫苗的复杂性,Moderna计划将其近期努力集中在使用当前版本的Spikevax的加强针上来解决Omicron的问题。

至于其 Omicron 特异性加强针 mRNA-1273.529,Moderna首席执行官 Stéphane Bancel 表示,该公司计划“迅速推进”候选药物进入临床测试。

与此同时,该公司公布了其 100μg Spikevax 加强针的 II/III 期试验的安全性结果。 Moderna 表示,来自 305 名参与者的数据表明,在接受加强接种 7 天后,引发的全身性和局部不良事件的频率和性质与接种两剂疫苗后的事件“大致相当”,但与50µg加强针相比,100µg加强针之后的不良反应率有所升高。

 

原始出处:

https://firstwordpharma.com/story/5465465

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1857981, encodeId=7d8e185e98179, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Aug 08 05:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084676, encodeId=4c2620846e6d6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Feb 26 06:40:02 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008810, encodeId=e2f7200881090, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Feb 28 07:40:02 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179536, encodeId=27d911e9536bd, content=疫苗价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sat Jan 01 14:14:10 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083281, encodeId=94631083281bd, content=学到了很多东西,谢谢各位老师的指导, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Wed Dec 22 23:28:55 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083211, encodeId=d4af10832113c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e01a1515602, createdName=huang7510, createdTime=Wed Dec 22 21:04:30 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083203, encodeId=862f108320344, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3961516447, createdName=azahuangli, createdTime=Wed Dec 22 20:48:46 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1857981, encodeId=7d8e185e98179, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Aug 08 05:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084676, encodeId=4c2620846e6d6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Feb 26 06:40:02 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008810, encodeId=e2f7200881090, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Feb 28 07:40:02 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179536, encodeId=27d911e9536bd, content=疫苗价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sat Jan 01 14:14:10 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083281, encodeId=94631083281bd, content=学到了很多东西,谢谢各位老师的指导, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Wed Dec 22 23:28:55 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083211, encodeId=d4af10832113c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e01a1515602, createdName=huang7510, createdTime=Wed Dec 22 21:04:30 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083203, encodeId=862f108320344, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3961516447, createdName=azahuangli, createdTime=Wed Dec 22 20:48:46 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2022-02-26 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=1857981, encodeId=7d8e185e98179, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Aug 08 05:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084676, encodeId=4c2620846e6d6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Feb 26 06:40:02 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008810, encodeId=e2f7200881090, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Feb 28 07:40:02 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179536, encodeId=27d911e9536bd, content=疫苗价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sat Jan 01 14:14:10 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083281, encodeId=94631083281bd, content=学到了很多东西,谢谢各位老师的指导, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Wed Dec 22 23:28:55 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083211, encodeId=d4af10832113c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e01a1515602, createdName=huang7510, createdTime=Wed Dec 22 21:04:30 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083203, encodeId=862f108320344, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3961516447, createdName=azahuangli, createdTime=Wed Dec 22 20:48:46 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2022-02-28 般若傻瓜
  4. [GetPortalCommentsPageByObjectIdResponse(id=1857981, encodeId=7d8e185e98179, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Aug 08 05:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084676, encodeId=4c2620846e6d6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Feb 26 06:40:02 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008810, encodeId=e2f7200881090, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Feb 28 07:40:02 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179536, encodeId=27d911e9536bd, content=疫苗价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sat Jan 01 14:14:10 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083281, encodeId=94631083281bd, content=学到了很多东西,谢谢各位老师的指导, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Wed Dec 22 23:28:55 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083211, encodeId=d4af10832113c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e01a1515602, createdName=huang7510, createdTime=Wed Dec 22 21:04:30 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083203, encodeId=862f108320344, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3961516447, createdName=azahuangli, createdTime=Wed Dec 22 20:48:46 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2022-01-01 病毒猎手

    疫苗价值

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1857981, encodeId=7d8e185e98179, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Aug 08 05:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084676, encodeId=4c2620846e6d6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Feb 26 06:40:02 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008810, encodeId=e2f7200881090, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Feb 28 07:40:02 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179536, encodeId=27d911e9536bd, content=疫苗价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sat Jan 01 14:14:10 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083281, encodeId=94631083281bd, content=学到了很多东西,谢谢各位老师的指导, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Wed Dec 22 23:28:55 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083211, encodeId=d4af10832113c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e01a1515602, createdName=huang7510, createdTime=Wed Dec 22 21:04:30 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083203, encodeId=862f108320344, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3961516447, createdName=azahuangli, createdTime=Wed Dec 22 20:48:46 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2021-12-22 1436749007

    学到了很多东西,谢谢各位老师的指导

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1857981, encodeId=7d8e185e98179, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Aug 08 05:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084676, encodeId=4c2620846e6d6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Feb 26 06:40:02 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008810, encodeId=e2f7200881090, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Feb 28 07:40:02 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179536, encodeId=27d911e9536bd, content=疫苗价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sat Jan 01 14:14:10 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083281, encodeId=94631083281bd, content=学到了很多东西,谢谢各位老师的指导, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Wed Dec 22 23:28:55 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083211, encodeId=d4af10832113c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e01a1515602, createdName=huang7510, createdTime=Wed Dec 22 21:04:30 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083203, encodeId=862f108320344, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3961516447, createdName=azahuangli, createdTime=Wed Dec 22 20:48:46 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2021-12-22 huang7510

    学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1857981, encodeId=7d8e185e98179, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Aug 08 05:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084676, encodeId=4c2620846e6d6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Feb 26 06:40:02 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008810, encodeId=e2f7200881090, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Feb 28 07:40:02 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179536, encodeId=27d911e9536bd, content=疫苗价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sat Jan 01 14:14:10 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083281, encodeId=94631083281bd, content=学到了很多东西,谢谢各位老师的指导, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Wed Dec 22 23:28:55 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083211, encodeId=d4af10832113c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e01a1515602, createdName=huang7510, createdTime=Wed Dec 22 21:04:30 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083203, encodeId=862f108320344, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3961516447, createdName=azahuangli, createdTime=Wed Dec 22 20:48:46 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2021-12-22 azahuangli

    学习

    0

相关资讯

基础科研:Omicron感染者流行病学研究发表,揭示了真实世界中的病情严重程度

丹麦的研究显示,该国Omicron病例从12月4日开始,每天增长40%。这意味着不到两天就翻一番。

FDA咨询小组支持默克公司的口服COVID-19药物,但无法确定是否对Omicron变种有效

本周二,FDA咨询小组以13票对10票的投票结果,建议默克公司的口服抗病毒药物molnupiravir紧急使用授权以治疗COVID-19。

2021年12月3日简报:新冠病毒奥密克戎(Omicron)变种可能是好事,或将加速终结新冠疫情,目前Omicron变种感染者均为轻症

截至北京时间2021年12月3日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿6436万例,新增636,862例,达到264,363,8

研究发现Omicron的繁殖速度比Delta快70倍,英国COVID-19病例超过75,000

Omicron 变体在人类呼吸道中的繁殖速度是 Delta 的 70 倍。然而,Omicron 变体在人类肺组织中的复制速度低于该病毒的原始毒株,这可能表明该疾病的严重程度较低。

新药进展:可有效预防Omicron!辉瑞新冠特效药Paxlovid预防死亡效力高达89%!

与安慰剂相比,在症状出现后三天内接受治疗的患者中,与 COVID-19 相关的住院或全因死亡减少了 89%,此外,观察到与中期分析一致的安全性特征。

拓展阅读

Neurology:感染Omicron住院COVID-19患者的神经系统疾病的发生率和长期功能结局

COVID-19相关的神经系统疾病的发生率在大流行病的预接种阶段有所下降。

Emerg Microbes Infect:COVID-19灭活疫苗对SARS-CoV-2 Omicron变体感染者中轻度疾病、肺炎和重症疾病的有效性

与原始Delta (B.1.617.2)变体相比,接种疫苗的个体对Omicron变体的中和抗体反应大大降低,尽管加强针增加了对Omicron变体的反应。

Infect Dis Ther:Paxlovid治疗老年人2019-冠状病毒Omicron变异株的安全性和有效性

omicron变异感染患者的住院率、住院时间、死亡率均较其他变异感染患者有所下降,且症状较轻。

NEJM:林丹瑜团队证实,二价mRNA疫苗加强针在预防Omicron的住院和死亡方面更有效

在预防重症和死亡方面,二价mRNA新冠疫苗作为加强针效果好于单价mRNA新冠疫苗作为加强针。

上海交大团队发现,重复接种灭活疫苗,会减弱突破性感染后对Omicron的中和抗体活性

一些研究显示,接种三剂新冠疫苗比接种两剂对Omicron具有更好的中和活性,但尚不清楚接种疫苗后的突破性感染,对接种三剂和接种两剂疫苗的人的免疫反应有何影响。

STTT:上海大学陈亮/空军军医大学朱平/边惠洁等合作发现Omicron变异株感染的免疫学和代谢特征

该研究报道了Omicron变异株感染的免疫学和代谢特征。该研究系统地研究了Omicron变异感染的免疫和代谢特征。